Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;12(3):236-239.
doi: 10.1111/cts.12626. Epub 2019 Mar 12.

Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration-Approved Drugs

Robert N Schuck  1 , Michael Pacanowski  1 , Sarah Kim  2 , Rajanikanth Madabushi  1 , Issam Zineh  1
Affiliations

Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration-Approved Drugs

Robert N Schuck et al. Clin Transl Sci. 2019 May.

Abstract

Selecting a dose regimen that is both safe and effective for patients is one of the most critical elements of a successful drug development program. Titrating the dose regimen of a drug based on patient response may help to identify safe and effective dosages at the individual patient level. Therefore, we quantified and characterized the use of response-guided titration for drugs recently approved by the US Food and Drug Administration (FDA) to assess how frequently this dosing strategy is used and how titration regimens are evaluated during drug development. Most of the 181 drugs approved from 2013-2017 (78%) had only one approved dosing regimen. Only 30 of 76 (39%) drugs that were considered amenable to response-guided dosing strategies had information in labeling about such strategies. These findings indicate that although response-guided titration can be found in labeling, this strategy is used in a minority of drugs for which it may be useful. Careful consideration should be made early in drug development as to whether a new drug is amenable to response-guided titration as an approach to reducing interpatient variability.

PubMed Disclaimer

Conflict of interest statement

The authors declared no competing interests for this work.

Figures

Figure 1
Figure 1
Number of dose regimens for drugs approved 2013–2017.
Figure 2
Figure 2
Use of response‐guided titration for drugs approved 2013–2017.
See this image and copyright information in PMC

References

    1. Cook, D. et al Lessons learned from the fate of Astrazeneca's drug pipeline: a five‐dimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014). - PubMed
    1. Sacks, L.V. , Shamsuddin, H.H. , Yasinskaya, Y.I. , Bouri, K. , Lanthier, M.L. & Sherman, R.E. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012. JAMA 311, 378–384 (2014). - PubMed
    1. Schuck, R.N. , Charlab, R. & Blumenthal, G.M. Leveraging genomic factors to improve benefit‐risk. Clin. Transl. Sci. 10, 78–83 (2017). - PMC - PubMed
    1. Cook, J.C. , Wu, H. , Aleo, M.D. & Adkins, K. Principles of precision medicine and its application in toxicology. J. Toxicol. Sci. 43, 565–577 (2018). - PubMed
    1. International Conference on Harmonisation. Efficacy guideline E4: dose‐response information to support drug registration <http://www.ich.org/products/guidelines/efficacy/article/efficacy-guideli...> (1994).

Substances

LinkOut - more resources